Menu
Market Place
Enquiry// Virchow Biotech: APIs needed for the U.S. market [EN00215-EN00216-EN00217-EN00218-EN00219]
Virchow Biotech, part of the $200 million Virchow Group of Companies, equipped with facilities to manufacture products ranging from orals and topical biologicals, recombinants to parental bio-pharmaceuticals is starting development of Regadenoson, Docosanol, Azealic Acid, Fluocinonide & Desoximetasone for the U.S. market.

14 Dec 2015

Reply

14 Dec 2015

Chat Comment (1)

Reply text-arrow